Do you want to read an article? Please log in or register.
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
Gallbladder and Biliary Diseases
Indications
Related content
Gastrointestinal Cancer
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Int J Cancer
Rimini M, Lamarca A, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Vogel A, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Landriscina M, Finkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Formica V, de Sousa Pinto CM, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan SL, Bolnykh I, Lancianese A, Satake T, Bekaii-Saab T, Lavacchi D, Passeri L, Ferrara M, Kang M, Viola MG, Bozzarelli S, Persano M, Masi G, Balsano R, Niger M, Lonardi S, Salani F, Camera S, Ratti F, Fornaro L, Rimassa L, Casadei-Gardini A
doi: 10.1002/ijc.70641
Helicobacter Pylori
Bismuth-Amoxicillin-Vonoprazan Triple, Amoxicillin-Vonoprazan Dual, and Clarithromycin-Based Triple Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Open-Label, Randomized Trial
Helicobacter
Hsu PI, Sheu MJ, Chen CL, Lei WY, Shih CA, Tsay FW, Kao SS, Shie CB, Wu PJ, Kuo CH, Yang JC, Chen KY, Chuah SK, Lee CL, Lee HC, Tai WC, Tsai TJ, Kao JY, Wu DC, Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium
doi: 10.1111/hel.70131
Gastrointestinal Cancer
Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial
Lancet Oncol
Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, West N, Quirke P, Sun Myint A, Bach S, Parsons P, Dhadda AS, Brown N, Brown G, Harrison M, Maggs R, Begum R, Chang E, Hackshaw A, Lopes A, ARISTOTLE Trial Management Group and Investigators
doi: 10.1016/S1470-2045(26)00132-4
Gastrointestinal Cancer
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
Lancet
Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E, Fakih M, Asghari G, So J, Stein A, Dubreuil O, Bodnar L, He CS, Wang G, Smith R, Eng C, Saeed A, STELLAR-303 study investigators
doi: 10.1016/S0140-6736(25)02025-2
Gastrointestinal Cancer
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
Lancet
Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J
doi: 10.1016/S0140-6736(26)01252-3
Esophagus Diseases
Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
Lancet Gastroenterol Hepatol
Takeuchi H, Machida R, Ando M, Tsubosa Y, Kikuchi H, Kawakubo H, Noma K, Ueno M, Tsushima T, Bamba T, Fujita T, Hamai Y, Kakishita T, Daiko H, Koyanagi K, Matsuda S, Kato K, Sasaki K, Kita R, Kitagawa Y, JCOG1409 investigators
doi: 10.1016/S2468-1253(25)00207-9
Gallbladder and Biliary Diseases
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial
J Hepatol
Kowdley KV, Bowlus CL, Levy C, Akarca U, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Elbeshbeshy H, Francque S, Heneghan MA, Invernizzi P, Jacobson IM, Jones D, Kremer AE, Kruger FC, Kugelmas M, Lawitz E, Mayo MJ, Shiffman ML, Sonderup M, Swain MG, Valera JM, Vierling JM, Villagrasa A, Villamil A, Antunes N, Raskino C, Sleiman M, Cranham V, Miller B, Schattenberg JM
doi: 10.1016/j.jhep.2026.08.016
Gastrointestinal Cancer
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)
Eur J Cancer
Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V
doi: 10.1016/j.ejca.2025.116105
Gastrointestinal Cancer
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer
Eur J Cancer
Dong Y, Pereyra D, Podrascanin V, Li Z, Santol J, Ammann M, Hardy N, Kankeu Fonkoua LA, Graham RP, Conboy CB, Tran NH, Warner SG, Smoot RL, Starlinger PP
doi: 10.1016/j.ejca.2026.116887